Skip to main content
NervGen Pharma Corp. logo

NervGen Pharma Corp. — Investor Relations & Filings

Ticker · NGEN ISIN · CA64082X2032 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 325 across all filing types
Latest filing 2025-05-07 Declaration of Voting R…
Country CA Canada
Listing TSXV NGEN

About NervGen Pharma Corp.

https://nervgen.com/

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on the discovery and development of pharmaceutical treatments designed to promote nervous system repair following neurologic trauma and disease. The company's core mission is to enable the nervous system to repair itself, offering a pharmacologic approach to conditions previously considered irreparable. Its lead drug candidate is NVG-291, a novel therapy currently in Phase 1b/2a clinical trials (CONNECT SCI Study) for individuals living with chronic spinal cord injury (SCI). Recent study data has demonstrated durable improvements in function and quality of life in this patient population. NervGen is also advancing its next-generation candidate, NVG-300, into preclinical proof-of-concept studies for three initial indications, expanding its pipeline for nervous system disorders.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a press release detailing the outcome of shareholder votes at the Annual General Meeting (AGM), including re-election of directors, auditor reappointment, and approval of stock option plan amendments. This fits the category “Declaration of Voting Results & Voting Rights Announcements.”
2025-05-07 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing the company’s participation and presentation at an upcoming investor conference. It does not contain financial results, Q&A, management discussion, an actual investor presentation deck, or any formal regulatory report. It is an investor relations announcement without substantive report content, so it falls under the general regulatory announcements fallback category.
2025-04-21 English
Management information circular - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a Management Proxy Circular accompanying a Notice of Meeting for the Annual General Meeting of NervGen Pharma Corp. It includes detailed proxy solicitation instructions, voting procedures, record dates, and descriptions of matters to be acted upon (e.g., election of directors, appointment of auditors). This corresponds to materials sent to shareholders to provide information and request votes for a shareholder meeting. Under the provided taxonomy, this is a Proxy Solicitation & Information Statement (PSI).
2025-04-10 English
Other.pdf
Regulatory Filings Classification · 0% confidence The document is simply a mailing request form for shareholders to opt in to receive interim or annual financial statements and MD&A by mail. It does not contain or announce the actual financial statements or results, nor does it fit any specific category like proxy solicitation, earnings release, or report itself. This falls into the miscellaneous regulatory communications fallback category.
2025-04-10 English
Other.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a Voting Instruction Form (“VIF”) for non-registered beneficial securityholders in advance of NervGen Pharma’s Annual General Meeting, providing proxy materials, voting instructions, and solicitation language. This is classic proxy solicitation material sent to shareholders to provide information and request votes for a meeting. Therefore it falls under Proxy Solicitation & Information Statement (PSI).
2025-04-10 English
Form of proxy - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a Form of Proxy solicited by management for an upcoming Annual General Meeting, containing voting instructions, appointment of proxyholder details, and solicitation of shareholder votes. This aligns precisely with "Proxy Solicitation & Information Statement" materials sent to shareholders to request votes for a meeting, fitting the PSI category.
2025-04-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.